Olmevas HZ 12.5/20 Tablet: Each film coated tablet contains 20 mg Olmesartan Medoxomil BP and 12.5 mg Hydrochlorothiazide BP.
Olmevas HZ 12.5/40 Tablet: Each film coated tablet contains 40 mg Olmesartan Medoxomil BP and 12.5 mg Hydrochlorothiazide BP.
Hydrochlorothiazide is a Thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of Sodium and Chloride in approximately equivalent amounts. Indirectly, the diuretic action of Hydrochlorothiazide reduces plasma volume with consequent increases in plasma renin activity, increases Aldosterone secretion & urinary Potassium loss and decreases serum Potassium. The renin-aldosterone link is mediated by angiotensin-II. Olmesartan is an angiotensin-II receptor blocker that acts on AT1 subtype. By blocking the action of angiotensin-II, Olmesartan dilates blood vessels and reduces blood pressure without affecting pulse rate.
Olmesartan and Hydrochlorothiazide combination indicated for the treatment of hypertension, alone or with other antihypertensive agents. Olmesartan and Hydrochlorothiazide combination may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Route of administration: The tablet should be taken orally.
Dosage: The usual recommended dosage of Olmesartan and Hydrochlorothiazide combination is one tablet once daily. Olmevas HZ 12.5/20 tablet may be administered in patients whose blood pressure is not adequately controlled by 20 mg Olmesartan Medoxomil or 12.5 mg Hydrochlorothiazide alone. Olmevas HZ 12.5/40 tablet may be administered in patients whose blood pressure is not adequately controlled by Olmesartan and Hydrochlorothiazide 12.5 mg/20 mg tablet.
*Prescription only*
With Medicine: The pharmacokinetics of Hydrochlorothiazide and Olmesartan or Hydrochlorothiazide are not altered when the drugs are co-administered.
With food & others: Absorption of Olmesartan or Hydrochlorothiazide are mostly unaffected by food.
Pregnancy: Pregnancy category D. When pregnancy is detected, discontinue Olmesartan and Hydrochlorothiazide combination as soon as possible.
Lactation: Should be avoided.
This medicine should not be given to children or adolescents (below the age of 18), because its benefits and risks have not been tested in these age groups.
Over dosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. In humans, experience with intentional over dosage of Hydrochlorothiazide is limited.
Store at below 30°C in a dry place, protected from light. Keep out of reach of children.